EpiSign Inc. Introduces EpiSign™ v6 with Expanded Episignature Coverage and Enhanced Classification

LONDON, ON, June 29, 2026 — EpiSign Inc. announces the release of EpiSign™ version 6 (v6), the latest advancement of its DNA methylation episignature classifier and analysis platform. EpiSign™ is a software platform that analyzes genome-wide DNA methylation patterns to identify disease-associated “episignatures”—distinct epigenetic biomarkers linked to specific rare genetic conditions. By comparing patient data […]

EpiSign Inc. is pleased to highlight its involvement in a newly funded Ontario Genomics initiative, “Synthetic Reference Epigenomics: Building a Secure Cloud Framework for Scalable Rare Disease Diagnostics.” The project focuses on developing secure, privacy-preserving infrastructure to enable large-scale epigenomic data analysis and collaboration. By leveraging synthetic reference datasets and cloud-based frameworks, the initiative aims to […]

TORONTO, March 25, 2025 /CNW/ – The Ontario Brain Institute (OBI) is pleased to announce a joint new initiative with EpiSign Inc., paving the way for improved diagnosis and care for people with rare neurological genetic disorders. Approximately 1 in 15 children are born with a rare genetic condition, many of which manifest in early childhood and require frequent […]